What does CELforPharma do?

CELforPharma is filed with the CBE under the catch-all “Overige zakelijke dienstverlening”. Also registered: recruitment agency, publisher, plastics manufacturer. Private Limited, started on 7 January 2005, 1 establishment.

What is the address of CELforPharma?

The registered office of CELforPharma is located at Jan Mommaertslaan 20 box a, 1831 Machelen (Brab.).

Is CELforPharma still active?

Yes. According to the CBE (29 October 2026) CELforPharma is active, legal situation “Normale toestand”, started on 7 January 2005.

Is CELforPharma registered on Peppol?

Yes, CELforPharma is registered on the Peppol network with ID 0208:0871088704.

What is the enterprise number of CELforPharma?

The enterprise number of CELforPharma is BE0871088704.

When was CELforPharma founded?

CELforPharma was founded on 7 January 2005.

Who are the directors of CELforPharma?

According to the 2025 annual accounts, the directors of CELforPharma are: LAICO4Growth BV.

Is CELforPharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 January 2005; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did CELforPharma make in 2025?

CELforPharma recorded a loss after taxes of € 21,251 in financial year 2025.

What is the revenue of CELforPharma?

As a small company, CELforPharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 149,685.

How much does an employee at CELforPharma earn?

The average wage cost per full-time employee at CELforPharma was € 66,900 in 2025: staff costs of € 133,710 for 2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does CELforPharma have?

According to the 2025 annual accounts, CELforPharma has 2 full-time equivalents (FTE).

CELforPharma (Private Limited) - Machelen (Brab.)

Dossier CELforPharma, printed on 29 October 2026 from databakkes.be/en/0871088704/celforpharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 4.2 to 2.

Financials

Financial year 2025

CELforPharma from Machelen (Brab.), company number BE0871088704, closed financial year 2025 with a result of € -21,251 after tax. For that financial year CELforPharma recorded a gross margin of € 149,685 and equity of € 323,248. Compared with financial year 2024, the result moved from € 37,590 to € -21,251. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 3, 2026.

What it is worth Healthy

€ 323,248

▼ 6% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -21,251

▼ still € 37,590 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 191,285

▲ 44% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 303,248.

People and assets in 2025

Full-time equivalents

▼ 0.5 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 133,710

▼ 19% vs 2024

€ 66,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 6,107

▼ 34% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 57,450

▲ 3% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 25,005

▲ 51% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 322,500 Gross margin 2022: € 322,500 First fiscal year in the series	€ 248,192 Gross margin 2023: € 248,192 ▼ 23% vs 2022 (€ 322,500) Unfavourable step	€ 233,885 Gross margin 2024: € 233,885 ▼ 6% vs 2023 (€ 248,192) Unfavourable step	€ 149,685 Gross margin 2025: € 149,685 ▼ 36% vs 2024 (€ 233,885) Unfavourable step	▼ 36%
Profit after taxes	€ 31,476 Profit after taxes 2022: € 31,476 First fiscal year in the series	€ -47,598 Profit after taxes 2023: € -47,598 ▼ € 79,075 vs 2022 (€ 31,476) Unfavourable step	€ 37,590 Profit after taxes 2024: € 37,590 ▲ € 85,189 vs 2023 (€ -47,598) Favourable step	€ -21,251 Profit after taxes 2025: € -21,251 ▼ € 58,842 vs 2024 (€ 37,590) Unfavourable step	▼ € 58,842
Equity	€ 354,507 Equity 2022: € 354,507 First fiscal year in the series	€ 306,909 Equity 2023: € 306,909 ▼ 13% vs 2022 (€ 354,507) Unfavourable step	€ 344,499 Equity 2024: € 344,499 ▲ 12% vs 2023 (€ 306,909) Favourable step	€ 323,248 Equity 2025: € 323,248 ▼ 6% vs 2024 (€ 344,499) Unfavourable step	▼ 6%
Total debts	€ 344,270 Total debts 2022: € 344,270 First fiscal year in the series	€ 246,838 Total debts 2023: € 246,838 ▼ 28% vs 2022 (€ 344,270) Favourable step	€ 231,119 Total debts 2024: € 231,119 ▼ 6% vs 2023 (€ 246,838) Favourable step	€ 296,699 Total debts 2025: € 296,699 ▲ 28% vs 2024 (€ 231,119) Unfavourable step	▲ 28%
Cash	€ 241,751 Cash 2022: € 241,751 First fiscal year in the series	€ 144,941 Cash 2023: € 144,941 ▼ 40% vs 2022 (€ 241,751) Unfavourable step	€ 132,932 Cash 2024: € 132,932 ▼ 8% vs 2023 (€ 144,941) Unfavourable step	€ 191,285 Cash 2025: € 191,285 ▲ 44% vs 2024 (€ 132,932) Favourable step	▲ 44%
Retained profit	€ 334,507 Retained profit 2022: € 334,507 First fiscal year in the series	€ 286,909 Retained profit 2023: € 286,909 ▼ 14% vs 2022 (€ 334,507) Unfavourable step	€ 324,499 Retained profit 2024: € 324,499 ▲ 13% vs 2023 (€ 286,909) Favourable step	€ 303,248 Retained profit 2025: € 303,248 ▼ 7% vs 2024 (€ 324,499) Unfavourable step	▼ 7%
Dividend	€ 30,000 Dividend 2022: € 30,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 30,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 698,777 Balance sheet total 2022: € 698,777 First fiscal year in the series	€ 553,747 Balance sheet total 2023: € 553,747 ▼ 21% vs 2022 (€ 698,777) Unchanged	€ 575,619 Balance sheet total 2024: € 575,619 ▲ 4% vs 2023 (€ 553,747) Unchanged	€ 619,947 Balance sheet total 2025: € 619,947 ▲ 8% vs 2024 (€ 575,619) Unchanged	▲ 8%
Employees (FTE)	4.4 Employees (FTE) 2022: 4.4 First fiscal year in the series	4.2 Employees (FTE) 2023: 4.2 ▼ 0.2 vs 2022 (4.4) Unchanged	2.5 Employees (FTE) 2024: 2.5 ▼ 1.7 vs 2023 (4.2) Unchanged	2 Employees (FTE) 2025: 2 ▼ 0.5 vs 2024 (2.5) Unchanged	▼ 0.5

Key figures of CELforPharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CELforPharma?

What happened at CELforPharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 3, 2026 New annual accounts for financial year 2025: loss of € 21,251 (▼ € 58,842 vs 2024). Source: NBB ↗
Jan 7, 2005 New establishment in Machelen (Brab.). KBO
Jan 7, 2005 Start of the company according to the CBE. KBO

In short

From € 31,476 profit in 2022 to € 21,251 loss in 2025.

Paid € 11,647 in corporate taxes since 2022.

Best year ever: 2024, with € 37,590 profit.

On average € 74,800 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

LAICO4Growth 100%

The stake of LAICO4Growth comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

CELforPharma

Behind CELforPharma is LAICO4Growth BV. The shares are held by LAICO4Growth (100%).

Directors

According to the 2025 annual accounts

LAICO4Growth BV

Director · represented by Annelies Swaan

Shareholders

LAICO4Growth

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Jan Mommaertslaan 20 box a

1831 Machelen (Brab.)

2.145.692.161

Jan Mommaertslaan 20a

1831 Machelen (Brab.)

Active since 7 January 2005

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.

All companies at this address →

VOCALCOM

€ 1.1 million gross margin · 2025

Lincoln Transition Executive

€ 254,215 revenue · 2024

The Captains

€ -27,764 gross margin · 2025

CrediBill

€ 203,904 gross margin · 2025

SOLIS ENERGY

€ -418 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0871.088.704

VAT number

BE 0871.088.704

Registered office

Jan Mommaertslaan 20 bus a, 1831 Machelen (Brab.)

Names & denominations

CELforPharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

7 January 2005

Peppol

Active · Active since 10 Jan 2025

Activities · NACE

Overige zakelijke dienstverlening, neg

Overige zakelijke dienstverlening, n.e.g.

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsvoering en beheer

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Arbeidsbemiddeling

Uitgeven van tijdschriften

Uitgeverijen van tijdschriften

View on CBE Public ↗ Annual accounts (NBB) ↗

CELforPharma

Warning lights

Financials

What happened to CELforPharma?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions